Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
E Dekking, YY Ng, VHJ Van der Velden, H Wai… - Leukemia, 2009 - nature.com
BCR–ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients.
F Weerkamp, E Dekking, YY Ng… - Leukemia …, 2009 - search.ebscohost.com
BCR–ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
[引用][C] Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, YY Ng, VHJ van der Velden… - Leukemia, 2009 - cir.nii.ac.jp
Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia
patients | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
patients | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
F Weerkamp, J Flores-Montero, A Orfao - 2009 - digital.csic.es
BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
[引用][C] Flow cytometric immunobead assay for the detection of BCR―ABL fusion proteins in leukemia patients
F WEERKAMP, E DEKKING, N VAN POECKE… - …, 2009 - pascal-francis.inist.fr
Author WEERKAMP, F 1 2; DEKKING, E 1 2; VAN POECKE, N 6; LUCIO, P 7; MENDONCA,
A 7; SEDEK, L 8; SZCZEPANSKI, T 8; KALINA, T 9; KOVAC, M 9; HOOGEVEEN, P. G 1; …
A 7; SEDEK, L 8; SZCZEPANSKI, T 8; KALINA, T 9; KOVAC, M 9; HOOGEVEEN, P. G 1; …
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.
F Weerkamp, E Dekking, YY Ng, VH van der Velden… - Leukemia, 2009 - europepmc.org
BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
[PDF][PDF] Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, YY Ng, VHJ van der Velden… - Leukemia, 2009 - researchgate.net
BCR–ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
F Weerkamp, L Dekking, YY Ng, V van der Velden… - Leukemia, 2009 - repub.eur.nl
BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, YY Ng… - …, 2009 - pubmed.ncbi.nlm.nih.gov
BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
[PDF][PDF] Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, YY Ng, VHJ van der Velden… - Leukemia, 2009 - academia.edu
BCR–ABL fusion proteins show increased signaling through their ABL tyrosine kinase
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …
domain, which can be blocked by specific inhibitors, thereby providing effective treatment …